LICENSE AGREEMENTS (Details) € in Thousands				1 Months Ended				3 Months Ended									6 Months Ended			12 Months Ended
	Aug. 05, 2021 USD ($)	Nov. 30, 2020 USD ($)	Jul. 30, 2020 USD ($)	Jan. 31, 2022 USD ($)	Sep. 30, 2016 USD ($)	Aug. 31, 2016 USD ($)	Jun. 30, 2016 USD ($) period	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2021 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Sep. 30, 2020 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)	Aug. 08, 2022 USD ($)	Jul. 15, 2022 USD ($)
Organization And Basis Of Presentation [Line Items]
License and related revenue								$ 0			$ 2,234,000						$ 0		$ 6,544,000
License agreement, royalty rate								2.00%									2.00%
Payments for restructuring																	$ 1,103,000
Transaction price														$ 11,200,000		$ 11,200,000				$ 11,200,000
Subsequent Event
Organization And Basis Of Presentation [Line Items]
Other receivable, asset purchase agreement																					$ 30,000,000	$ 70,000,000
Qilu Pharmaceutical Co., Ltd. | Licensing Agreements
Organization And Basis Of Presentation [Line Items]
Potential milestone payments												$ 23,000,000
License and related revenue											$ 900,000	2,800,000				$ 11,200,000
Upfront payment			$ 12,000,000																	12,000,000
Total milestone payments			$ 23,000,000
Royalty payment, percentage			12.00%
Business combination, milestone payments												3,000,000
University of Zurich
Organization And Basis Of Presentation [Line Items]
Royalty payment obligation, percent																	4.00%	4.00%
Third party maximum ownership, percent																	10.00%	10.00%
Third party minimum ownership, percent																	2.00%	2.00%
Expenses related to achievement of development milestone										$ 500,000				300,000
University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone																	$ 500,000
Micromet AG
Organization And Basis Of Presentation [Line Items]
Royalty payment obligation, percent																	3.50%	3.50%
Expenses related to achievement of development milestone												600,000	€ 500	900,000	€ 700
Potential milestone payments																	$ 2,500,000	€ 2,400
License agreement, royalty payment, reduction, conditions not met																	1.50%	1.50%
License maintenance fees																	$ 52,148	€ 50
XOMA Ireland Limited
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone																	$ 250,000
Royalty payment obligation, percent																	2.50%	2.50%
Third party maximum ownership, percent																	50.00%	50.00%
Third party minimum ownership, percent																	1.75%	1.75%
Roche
Organization And Basis Of Presentation [Line Items]
License agreement, up-front fee						$ 7,500,000
License agreement, additional up-front fee						262,500,000
Milestone achieved									$ 20,000,000
License agreement, option periods | period							2
License agreement, buyout amount under first option period							$ 135,000,000
License agreement, period to pay buyout option once exercised							30 days
License agreement, buyout amount under second option period							$ 265,000,000
Buyout amount under second option period							$ 220,000,000
Roche | EBI-031
Organization And Basis Of Presentation [Line Items]
Milestone achieved								$ 20,000,000	20,000,000								$ 20,000,000
Payment terms																	30 days	30 days
License and related revenue									$ 20,000,000
Proceeds from milestone achieved				$ 20,000,000
Roche | EBI-031 | Minimum
Organization And Basis Of Presentation [Line Items]
License agreement, royalty rate								7.50%									7.50%
Roche | EBI-031 | Maximum
Organization And Basis Of Presentation [Line Items]
License agreement, royalty rate								15.00%									15.00%
Roche | First Indication
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone						197,500,000
Roche | Collaborative arrangement, revenue based on development milestone
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone						72,500,000
Roche | Collaborative arrangement, revenue based on development milestone | EBI-031
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone					$ 22,500,000
Roche | Collaborative Arrangement, Revenue Based on Development Milestone, Phase II
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone						30,000,000
Roche | Collaborative arrangement, revenue based on regulatory milestone
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone						50,000,000
Roche | Collaborative arrangement, revenue based on commercialization milestone
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone						$ 75,000,000
Roche | Second Indication
Organization And Basis Of Presentation [Line Items]
License agreement, amount payable upon achievement of specified milestone																	$ 65,000,000
Qilu Pharmaceutical Co., Ltd.
Organization And Basis Of Presentation [Line Items]
Royalty period			12 years
MENA License Agreement | Licensing Agreements
Organization And Basis Of Presentation [Line Items]
License and related revenue												$ 1,500,000
Upfront payment		$ 3,000,000
Transaction price														$ 1,500,000						$ 1,500,000
Royalty revenue, percentage														0.50						0.50
Deferred revenue								$ 1,500,000									$ 1,500,000
Eczacibasi Pharmaceuticals Marketing Agreement
Organization And Basis Of Presentation [Line Items]
Potential milestone payments	$ 2,000,000
Transaction price	$ 1,500,000
Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY
Organization And Basis Of Presentation [Line Items]
Royalty revenue, percentage	0.30